Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
344 Avelumab + binimetinib in metastatic pancreatic ductal adenocarcinoma (mPDAC): dose-escalation results from the phase 1b/2 JAVELIN PARP MEKi trial
Compose a Response to This Article
Other responses
No responses have been published for this article.